IREB2 Protein
Overview
Iron regulatory protein 2 (IRP2), encoded by the IREB2 gene on chromosome 14q24.1, is a critical post-transcriptional regulator of iron homeostasis in cells throughout the body, with particular importance in the nervous system. IRP2 belongs to a family of iron-responsive RNA-binding proteins that coordinate cellular iron metabolism by sensing intracellular iron concentrations and adjusting gene expression accordingly. The protein functions as a molecular "iron sensor" that detects changes in iron availability and triggers adaptive responses to maintain iron balance—preventing both iron deficiency and iron overload, both of which are toxic to neurons. This regulatory function is especially important in the brain, which has high energy demands and requires iron for critical enzymatic processes including ATP production, myelin synthesis, and antioxidant defense.
Function/Biology
IRP2 exerts its regulatory effects through a reversible binding mechanism involving iron-responsive elements (IREs), which are conserved stem-loop structures found in the 5' and 3' untranslated regions (UTRs) of target mRNAs. When cellular iron levels are low, IRP2 adopts an active conformation that binds efficiently to IREs with high affinity. This binding blocks ribosome access to target mRNAs, inhibiting translation of proteins involved in iron uptake and storage. Conversely, when iron concentrations rise, iron-dependent aconitase activity increases, producing citrate that indirectly leads to IRP2 inactivation through post-translational modifications. IRP2 can be phosphorylated, ubiquitinated, and targeted for proteasomal degradation when iron levels are adequate, reducing its RNA-binding capacity.
The primary targets of IRP2 regulation include transferrin receptor 1 (TfR1), which mediates iron uptake; ferritin heavy chain (FTH1) and ferritin light chain (FTL), which sequester excess iron; and divalent metal transporter 1 (DMT1), which facilitates iron absorption. Through these regulatory interactions, IRP2 maintains cellular iron concentrations within a narrow physiological range—typically 200-300 micromolar in most cells, but lower in neurons due to their specialized requirements.
Role in Neurodegeneration
Dysregulated iron metabolism has emerged as a central contributor to multiple neurodegenerative diseases, with IRP2 dysfunction implicated in Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Alzheimer's disease (AD). In PD, iron accumulates in the substantia nigra, particularly in dopamine-producing neurons, where it catalyzes formation of harmful reactive oxygen species through Fenton chemistry, promoting neuronal death. Studies of post-mortem PD brain tissue and animal models demonstrate reduced IRP2 activity or altered IRP2 expression, leading to impaired iron export and progressive iron accumulation in vulnerable neurons.
In ALS, defective iron handling contributes to motor neuron degeneration through multiple pathways. IRP2 dysregulation can lead to increased ferritin expression without corresponding improvements in iron detoxification, or conversely, insufficient iron sequestration allowing free iron to damage cellular components. In AD, cerebral iron accumulation near amyloid-beta plaques promotes oxidative stress and neuroinflammation, processes potentially involving IRP2 dysregulation.
Molecular Mechanisms
The iron-sensing mechanism involves the [4Fe-4S] iron-sulfur cluster assembly pathway. When cellular iron is abundant, proteins like GLRX3/BOLA3 and ferredoxin-2 facilitate synthesis of [4Fe-4S] clusters that accumulate in cells. These iron-sulfur clusters indirectly promote IRP2 ubiquitination through the E3 ubiquitin ligase FBXL5 in an iron-dependent manner, targeting IRP2 for degradation. Additionally, iron regulates IRP2 through mitochondrial dysfunction; excessive iron impairs mitochondrial electron transport, reducing ATP production and altering calcium homeostasis, both of which affect IRP2 stability and activity through poorly understood mechanisms.
IRP2 phosphorylation by kinases including PKA can enhance or diminish its RNA-binding capacity depending on phosphorylation site and cellular context, providing additional regulatory layers responsive to neuronal signaling.
Clinical/Research Significance
IRP2-targeted interventions represent promising therapeutic strategies for iron-related neurodegeneration. Approaches include iron chelators to reduce free iron availability, antioxidants to mitigate iron-catalyzed oxidative damage, and drugs targeting IRP2 stabilization or degradation depending on disease context. Understanding IRP2 regulation offers insights into shared pathological mechanisms across neurodegenerative diseases and may enable development of disease-modifying therapies.
- [IREB1](/proteins/ireb1) - Iron regulatory protein 1, functional homolog of IRP2
- [TfR1](/proteins/tfr1) - Transferrin receptor 1, primary IRP2 target
- [Ferritin](/proteins/ferritin) - Iron storage protein complex regulated by IRP2
- [FBXL5](/proteins/fb